(Q52209373)

27 April 2018

title

Continual reassessment methods in phase I trials of the combination of two drugs in oncology. (English)

1 reference

27 April 2018

main subject

phase I clinical trial

0 references

author name string

A Kramar

series ordinal

1

1 reference

27 April 2018

A Lebecq

series ordinal

2

1 reference

27 April 2018

E Candalh

series ordinal

3

1 reference

27 April 2018

language of work or name

English

0 references

publication date

1 July 1999

1 reference

27 April 2018

published in

Statistics in Medicine

1 reference

27 April 2018

volume

18

1 reference

27 April 2018

issue

14

1 reference

27 April 2018

page(s)

1849-1864

1 reference

27 April 2018

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Phase I trial design: are new methodologies being put into practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Design and analysis of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Using toxicity grades in the design and analysis of cancer phase i clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Continual reassessment method: a likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Some practical improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

The expected effect of a combination of agents: the general solution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Improved designs for dose escalation studies using pharmacokinetic measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Practical modifications of the continual reassessment method for phase I cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

A random walk rule for phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Accelerated titration designs for phase I clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0258%2819990730%2918%3A14%3C1849%3A%3AAID-SIM222%3E3.0.CO%3B2-I

10.1002/(SICI)1097-0258(19990730)18:14<1849::AID-SIM222>3.0.CO;2-I

21 January 2018

Identifiers

DOI

1 reference

27 April 2018

1 reference

27 April 2018